Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C | BMS Newsroom

U.S. application submission marks third major daclatasvir regulatory milestone globally, follows E.U. and Japan



Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C | BMS Newsroom